Top 5 Most-Read Articles About Automated Insulin Delivery in 2022
Content published on AJMC.com focusing on automated insulin delivery devices over the past year highlighted utilization of these devices by age, compared different types of systems, looked at barriers to uptake, and examined equity issues standing in the way of access.
What We’re Reading: Lilly Diabetes Drug Shortage; Medicare Data Breach; New Model for Antibiotics
Eli Lilly is experiencing a shortage of the diabetes drug tirzepatide (Mounjaro); a data breach has caused over 200,000 Medicare enrollees to receive new identification cards; a restructuring of the current model for developing and selling antibiotics could be a solution to shortages and drug-resistant germs.
Multiple Barriers Inhibit Optimal Treatment of Endometriosis: Dr Robin Kroll
Women with endometriosis may experience a delay in optimal care due to a variety of reasons including cultural beliefs, prior authorization hurdles, and more, explained Robin Kroll, MD, medical director, Seattle Clinical Research Center
Marcia Horn Discusses Advancements in EGFR Exon 20 Insertion+ NSCLC and the Importance of Community
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access to programs to navigate their care.
ICYMI: Top Highlights From ACC 2022
The American College of Cardiology’s 71st Scientific Session covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.
What We're Reading: Stress Aged Teenage Brains; WA Flu Deaths; Physicians File Brief in ACA Case
Teenage brains prematurely aged by 3 years during pandemic lockdowns; Washington state health officials report high flu activity and 7 deaths; medical groups ask a Texas judge to refrain from issuing a nationwide injunction against the preventive health screenings covered by the Affordable Care Act (ACA).
Stopping Methotrexate for 1 Week After Flu Vaccine May Work as Well as 2 Weeks
Methotrexate dampens the immune response to vaccines, and a recent study showed that discontinuing treatment for 1 week instead of 2 worked just as well for patients with rheumatoid arthritis getting a flu shot.